
Annual report 2024
added 12-06-2025
Alcon Financial Ratios 2011-2026 | ALC
Annual Financial Ratios Alcon
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | - | - | 113.2 | -60.4 | -41.9 | - | 157.4 | - | - | - | - | - | - |
P/S |
- | - | - | 5.1 | 4.7 | 3.7 | - | 5.9 | - | - | - | - | - | - |
EPS |
- | - | - | 0.8 | -1.1 | -1.3 | -0.5 | 0.5 | - | - | - | - | - | - |
EV (Enterprise Value) |
7.12 B | 7.9 B | 8.51 B | 49.7 B | 39.3 B | 35 B | 4.2 B | 44.5 B | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | 1.18 | -0.99 | -0.38 | - | -0.16 | - | - | - | - | - | - |
EV/EBITDA |
72.7 | 31.6 | 26.1 | - | 1.7 | 0.1 | 0.0 | - | - | - | - | |||
PEG |
- | -3.46 | 0.24 | - | 0.03 | - | - | - | - | - | - | |||
P/B |
- | - | - | 2.2 | 1.7 | 1.4 | - | 1.7 | - | - | - | - | - | - |
P/CF |
- | - | - | 31.6 | 39.0 | 29.9 | - | 33.1 | - | - | - | - | - | - |
ROE % |
- | - | - | - | -2.82 | -3.40 | -1.00 | 1.11 | -0.74 | 1.30 | - | - | - | - |
ROA % |
- | - | - | 1.34 | -1.92 | -2.37 | -0.84 | 0.93 | -0.61 | 1.09 | - | - | - | - |
ROCE % |
- | - | - | - | -2.56 | -0.74 | -0.99 | -0.30 | -0.31 | 1.39 | - | - | - | - |
Current Ratio |
3.5 | 3.3 | 3.1 | 3.2 | 3.1 | 3.3 | 6.1 | 6.3 | 1.8 | 1.8 | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | 71.0 | 62.8 | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | 126.4 | 118.8 | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | 63.6 | 63.7 | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | 197.4 | 181.6 | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | 133.8 | 117.9 | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Alcon
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | 0.31 | - | - | - | -0.86 | - | - | - | -0.8 | - | - | - | 0.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | 0.46 | - | - | - | -0.95 | - | - | - | -0.11 | - | - | - | 0.08 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
- | - | 0.79 | 1.58 | 1.58 | 0.79 | -1.46 | -4.50 | -4.50 | -2.25 | -4.25 | -4.01 | -4.01 | -2.00 | -1.94 | 0.13 | 0.13 | 0.07 | 0.07 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
- | - | 0.54 | 1.09 | 1.09 | 0.54 | -0.99 | -3.07 | -3.07 | -1.54 | -2.94 | -2.81 | -2.81 | -1.40 | -1.40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | - | 0.90 | 1.79 | 1.79 | 0.90 | -0.94 | -3.67 | -3.67 | -1.83 | -2.06 | -0.44 | -0.44 | -0.22 | -0.05 | 0.33 | 0.33 | 0.17 | 0.17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | 3.2 | - | 3.2 | - | 3.1 | - | 3.2 | - | 3.3 | - | 3.3 | - | 6.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Alcon, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 20.11 | 3.08 % | $ 10.3 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 199.29 | 2.23 % | $ 57.3 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.32 | 6.19 % | $ 168 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.69 | 6.06 % | $ 29.3 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
iRhythm Technologies
IRTC
|
$ 185.48 | 5.86 % | $ 5.79 B | ||
|
AtriCure
ATRC
|
$ 40.81 | 3.91 % | $ 1.92 B | ||
|
Repro Med Systems
KRMD
|
$ 5.59 | -0.36 % | $ 255 M | ||
|
electroCore
ECOR
|
$ 4.75 | 4.29 % | $ 26.2 K | ||
|
LeMaitre Vascular
LMAT
|
$ 82.24 | 2.58 % | $ 1.85 B | ||
|
ICU Medical
ICUI
|
$ 144.42 | 4.25 % | $ 3.52 B | ||
|
AngioDynamics
ANGO
|
$ 13.22 | 4.22 % | $ 540 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
$ 83.19 | 2.56 % | $ 16.6 B | ||
|
Merit Medical Systems
MMSI
|
$ 88.65 | 2.54 % | $ 5.16 B | ||
|
Glaukos Corporation
GKOS
|
$ 113.43 | 2.38 % | $ 5.49 B | ||
|
Haemonetics Corporation
HAE
|
$ 81.85 | 2.31 % | $ 4.12 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.79 | 4.77 % | $ 182 M | ||
|
Nephros
NEPH
|
$ 4.93 | 3.79 % | $ 51.2 M | ||
|
Masimo Corporation
MASI
|
$ 133.69 | 4.94 % | $ 7.13 B | ||
|
OraSure Technologies
OSUR
|
$ 2.47 | 3.78 % | $ 184 M | ||
|
Intuitive Surgical
ISRG
|
$ 564.19 | 0.39 % | $ 200 B | ||
|
Microbot Medical
MBOT
|
$ 2.1 | -0.71 % | $ 21.4 M | ||
|
Milestone Scientific
MLSS
|
$ 0.3 | 2.44 % | $ 23.9 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 22.52 | 3.92 % | $ 3.88 B | ||
|
STERIS plc
STE
|
$ 256.06 | 2.43 % | $ 25.2 B | ||
|
Stereotaxis
STXS
|
$ 2.4 | 3.66 % | $ 194 M | ||
|
Pro-Dex
PDEX
|
$ 38.78 | 2.81 % | $ 128 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 32.4 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.89 | 11.2 % | $ 715 M | ||
|
Utah Medical Products
UTMD
|
$ 58.16 | 2.94 % | $ 211 M | ||
|
Repligen Corporation
RGEN
|
$ 169.9 | 3.38 % | $ 9.47 M | ||
|
ResMed
RMD
|
$ 245.71 | 0.37 % | $ 35.9 B | ||
|
BioLife Solutions
BLFS
|
$ 25.31 | 5.94 % | $ 1.17 B | ||
|
Retractable Technologies
RVP
|
$ 0.76 | 0.01 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
$ 24.0 | 1.69 % | $ 1.18 B | ||
|
Teleflex Incorporated
TFX
|
$ 124.76 | 1.84 % | $ 5.84 B | ||
|
West Pharmaceutical Services
WST
|
$ 278.29 | 0.68 % | $ 20.3 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.7 | 3.77 % | $ 2.38 B |